Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Cesar Rodriguez, MD, Roy Ervin Strowd III, MD, David D Grier

Blood (2017) 130 (Supplement 1): 5410.

https://doi.org/10.1182/blood.V130.Suppl_1.5410.5410

Published: 2017

Journal Articles

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

John A Lust, MD, PhD, Martha Q Lacy, MD, Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Laurie L. Moon-Tasson, BA, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2011) 118 (21): 2945.

https://doi.org/10.1182/blood.V118.21.2945.2945

Published: 2011

Journal Articles

Triclonality in Immunofixation in Multiple Myeloma – Artifact of Therapy, Patient Characteristic or Proper Diagnosis?

Gilberto P Marques, MD, Marta I Pereira, MD, Rosário Cunha, MD, Fernando Rodrigues, MD, Graça Ribeiro, MD

Blood (2011) 118 (21): 5094.

https://doi.org/10.1182/blood.V118.21.5094.5094

Published: 2011

Journal Articles

Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival

Sarah K. Johnson, PhD, Peter Stewart, PhD, Shmuel Yaccoby, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 1813.

https://doi.org/10.1182/blood.V118.21.1813.1813

Published: 2011

Journal Articles

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Suzanne Hayman, MD, Morie Gertz, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Susan Geyer, PhD, Shaji Kumar, MD, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, John Lust, MD, PhD, Robert Kyle, MD, Philip Greipp, MD, Thomas Witzig, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3568.

https://doi.org/10.1182/blood.V108.11.3568.3568

Published: 2006

Journal Articles

Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.

Harris V.K. Naina, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Shaji Kumar, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Morie A. Gertz, MD, S. Vincent Rajkumar, MD

Blood (2005) 106 (11): 3475.

https://doi.org/10.1182/blood.V106.11.3475.3475

Published: 2005

NARROW

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Triclonality in Immunofixation in Multiple Myeloma – Artifact of Therapy, Patient Characteristic or Proper Diagnosis?

Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Triclonality in Immunofixation in Multiple Myeloma – Artifact of Therapy, Patient Characteristic or Proper Diagnosis?

Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only